Fig. 2From: Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOWChange in visual acuity over 12 and 24 months according to intravitreal aflibercept regimen. Observed analysis. *P < 0.05 versus baseline. BCVA best-corrected visual acuity, FAS full analysis set, IDs, initial doses, irreg irregular, reg regular, n number or patientsBack to article page